Study of Individual-level progression of COVID-19 infection (COVIDprog)
- Funded by Finnish Institute for Health and Welfare
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$0Funder
Finnish Institute for Health and WelfarePrincipal Investigator
Professor Markus PerolaResearch Location
FinlandLead Research Institution
Finnish Institute for Health and WelfareResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The aim of the national COVIDprog study is to investigate the impact of different individual factors on the course of coronavirus infection, particularly among those who develop the severe form of coronavirus disease (COVID-19). Study objectives The aim of the national COVIDprog study is to investigate the impact of different individual factors on the course of coronavirus infection, particularly among those who develope the severe form of the coronavirus disease (COVID-19). The study examines the progress of coronavirus infection in different individuals and what symptoms it causes. Major individual variation has been observed in the course of the respiratory infections caused by the new coronavirus. There is individual (including genetic) susceptibility to infections caused by bacteria and viruses and their associated diseases. This may be one explanation for the variation observed in the infectiousness of coronavirus disease (COVID-19) between individuals, for the progression of the infection and the secondary diseases and other harmful effects related to it. Potential individual-level factors that may affect the transmission and progression of COVID-19 include, for example: age, gender, lifestyles chronic diseases medication(s) genome received treatment. It is important to explore why some people develop a more severe form of the COVID-19 disease than others. The results of this study will be used to plan the future treatment and prevention of the COVID-19 infections. Coronavirus COVID-19 Coronavirus COVID-19 - Latest Updates How is the study carried out? The goal is to involve in the study more than 3000 persons who have sought hospital treatment or examinations due to respiratory symptoms, which may be caused by a COVID-19 infection. Also participants with milder respiratory symptoms will be recruited in the study. The control group will include persons tested negative for COVID-19. Participation in the study is voluntary. We ask participants to fill in a short health questionnaire in order to gather information about their general health and lifestyle. A blood sample is collected from the participants and analysed in the laboratory to investigate the severity of the infection and general physiological homeostasis of the patient. A DNA sample is extracted from the blood sample to determine the possible effect of genetic factors on the course of the corona virus infection. Further, health status of the study participants will be followed by medical records collected during the hospital treatment, including clinical measurements as well as laboratory and X-ray examinations as well as by acquiring access to relevant national registries, including: the statutory registers of the National Institute for Health and Welfare (e.g. Care Register for Health Care, Finnish Cancer Registry, National Infectious Diseases Register, National Vaccination Register), the registers of Statistics Finland (e.g. Causes of Death Information), and the registers of the Social Insurance Institution of Finland (e.g. Drug Reimbursement Register). The data permit for the use of register data is applied for and the actual register data is retrieved through the health and social data permit authority Findata (www.findata.fi).